Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
10 2023
Historique:
revised: 18 07 2023
received: 08 05 2023
accepted: 13 08 2023
medline: 23 10 2023
pubmed: 7 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed to extend the psychedelic experience and potential therapeutic effects. The primary aim of this work was to design an infusion protocol for DMT based on a desired level of psychedelic intensity using population pharmacokinetic/pharmacodynamic modeling. As a secondary aim, the impact of choosing a continuous variable or a bounded integer pharmacokinetic/pharmacodynamic model to inform such an infusion protocol was investigated. A previously published continuous variable model and two newly developed bounded integer models were used to assess optimal doses for achieving a target response. Simulations were performed to identify an optimal combination of a bolus dose and an infusion rate. Based on the simulations, optimal doses to achieve intensity ratings between 7 and 9 (possible range = 0-10) were a bolus dose of 16 mg DMT fumarate followed by an infusion rate of 1.4 mg/min based on the continuous variable model and 14 mg with 1.2 mg/min for the two bounded integer models. However, the proportion within target was low (<53%) for all models, indicating that individual dose adjustments would be necessary. Furthermore, some differences between the models were observed. The bounded integer models generally predicted lower proportions within a target of 7-9 with higher proportions exceeding target compared with the continuous variable model. However, results varied depending on target response with the major differences observed at the boundaries of the scale.

Identifiants

pubmed: 37675853
doi: 10.1002/psp4.13037
pmc: PMC10583250
doi:

Substances chimiques

Hallucinogens 0
N,N-Dimethyltryptamine WUB601BHAA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1398-1410

Informations de copyright

© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1398-1410
pubmed: 37675853
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
AAPS J. 2019 Jun 6;21(4):74
pubmed: 31172350
Sci Rep. 2019 Nov 19;9(1):16324
pubmed: 31745107
J Psychoactive Drugs. 2019 Sep-Oct;51(4):299-310
pubmed: 31018803
Neuropsychopharmacology. 2022 Sep;47(10):1854-1862
pubmed: 35660802
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Front Pharmacol. 2016 Jul 14;7:211
pubmed: 27471468
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404
pubmed: 15000421
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596
pubmed: 27730482
Clin Transl Sci. 2022 Dec;15(12):2928-2937
pubmed: 36088656
Arch Gen Psychiatry. 1994 Feb;51(2):85-97
pubmed: 8297216
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):311-327
pubmed: 37086340
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
ACS Pharmacol Transl Sci. 2020 Dec 10;4(2):568-572
pubmed: 33861219
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
Clin Pharmacol Ther. 1979 Mar;25(3):358-71
pubmed: 761446
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051

Auteurs

Emma Eckernäs (E)

Unit for Pharmacokinetics and Drug Metabolism, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Jeroen Koomen (J)

Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Christopher Timmermann (C)

Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.

Robin Carhart-Harris (R)

Psychedelics Division, Neuroscape, Department of Neurology, University of California San Francisco, San Francisco, California, USA.

Daniel Röshammar (D)

Pharmetheus AB, Uppsala, Sweden.

Michael Ashton (M)

Unit for Pharmacokinetics and Drug Metabolism, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH